There are a number of trastuzumab biosimilars available, but so far there have not been any patient characteristics that have played a role in which ones are prescribed, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium.
There are a number of trastuzumab biosimilars available, but so far there have not been any patient characteristics that have played a role in which ones are prescribed, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium.
Transcript
How does patient characterization play a role in the use of trastuzumab biosimilars?
You know, so far, no. In our preliminary analysis, we haven't seen any real differences in patient populations who are treated with one or another. It's possible that there are some regional differences. We don't tend to tease that out. Our population in the databases that we work with are fairly broadly distributed around the United States. And we're also looking at commercially insured population. So, there's some limitations for our particular data set.
But in terms of the basic patient characteristics, we haven't really seen anything notably different across them.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More